Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors.

ABSTRACT: Meningiomas account for one-third of all primary brain tumors. Although typically benign, about 20% of meningiomas are aggressive, and despite the rigor of the current histopathological classification system there remains considerable uncertainty in predicting tumor behavior. Here, we analyzed 160 tumors from all 3 World Health Organization (WHO) grades (I through III) using clinical, gene expression, and sequencing data. Unsupervised clustering analysis identified 3 molecular types (A, B, and C) that reliably predicted recurrence. These groups did not directly correlate with the WHO grading system, which classifies more than half of the tumors in the most aggressive molecular type as benign. Transcriptional and biochemical analyses revealed that aggressive meningiomas involve loss of the

SUBMITTER: Patel AJ 

PROVIDER: S-EPMC6815170 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature